- Company
- GC Biopharma’s Hunterase approved after 11yrs
- by Chon, Seung-Hyun Nov 17, 2023 05:59am
- GC Biopharma’s rare disease treatment ‘Hunterase’ was granted official marketing authorization 11 years after receiving conditional approval. On the 16th, GC Biopharma announced that it had completed the Phase III trial for its Hunterase on the 14th and changed its license from conditional approval to final marketing authorization.
- Company
- Will Keytruda’s receive reimb for TNBC in KOR?
- by Eo, Yun-Ho Nov 17, 2023 05:59am
- Whether MSD Korea will be able to make progress in extending reimbursement for its cancer immunotherapy Keytruda for the 13 additional indications it had applied for is receiving attention. According to industry sources, 3 indications of MSD Korea’s PD-1 inhibitor Keytruda (pembrolizumab) are expected to be deliberated by the Health Insu
- Company
- Large companies more actively engage in patent challenges
- by Kim, Jin-Gu Nov 17, 2023 05:59am
- Pharmaceutical and bio companies with annual sales of more than KRW 300 billion were found to be most actively engaging in patent challenges. As of 2021, pharmaceutical companies with sales exceeding KRW 300 billion applied for an average of 7.7 generic exclusivity approvals per company. The average number of applications for generic exclusiv
- Company
- GI Innovation registers patent in US for its GI-101/GI-102
- by Nho, Byung Chul Nov 16, 2023 05:46am
- GI Innovation announced on the 15th that it had registered patents for its immune-oncology drug GI-101/GI-102 in combination with various anticancer drugs. The company registered the patent for 101/GI-102 for broad application with global blockbuster anticancer drugs such as PARP inhibitors, CDK4/6 inhibitors, and VEGFR inhibitors, allo
- Company
- Poteligel can be prescribed at hospitals
- by Eo, Yun-Ho Nov 15, 2023 05:39am
- 'Mycobacterial Breed' and 'Poteligel', a treatment for 'siary syndrome', have entered the prescription of a general hospital. According to the relevant industry, Korea Kyowa Kirin's Poteligio (Mogamulijumab) has passed the Drug Committee (DC) of medical institutions such as Seoul Asan Hospital. Potelio passed the Cancer Disease Review
- Company
- Korean bio companies intent on developing new AD drugs
- by Son, Hyung-Min Nov 15, 2023 05:39am
- Despite downturns, including the return of the rights for JW Pharmaceutical’s atopic dermatitis drug candidate, clinical trials for new drugs to treat atopic dermatitis are still ongoing in Korea. Last month, JW Pharmaceutical announced that its technology transfer agreement for its atopic dermatitis treatment JW1601 which it signed with the
- Company
- Will the new ADC breast cancer drug Trodelvy be reimb?
- by Eo, Yun-Ho Nov 15, 2023 05:39am
- ‘Trodelvy,’ another new ADC drug for breast cancer, is seeking reimbursement listing in Korea. According to industry sources, Gilead Science Korea has submitted an application for the reimbursement of its triple-negative breast cancer treatment Trodelvy (sacituzumab govitecan-hziy) on July 31, and the agenda is awaiting to be presented
- Company
- Market for montelukast revive…overcomes impurity issue
- by Kim, Jin-Gu Nov 14, 2023 05:49am
- The market for asthma treatments containing the ingredient montelukast has succeeded in complete revival. This market shrank significantly in 2020-2021 due to the side effects issue and the COVID-19 outbreak, but made a rebound last year, and is expected to expand to the largest size ever this year. The market which remained stagnant fo
- Company
- Conquest of low survival gallbladder cancer
- by Nov 14, 2023 05:49am
- In the area of bile duct cancer, where survival rates are low and treatment options are scarce, new drug candidates from domestic pharmaceutical companies have been confirmed in clinical practice and are one step closer to commercialization. HDB001A, a new drug candidate for gallbladder cancer that Handok is developing, has recently been approve
- Company
- Novartis loses 2nd trial for its Entresto patent
- by Kim, Jin-Gu Nov 13, 2023 05:23am
- The second trial over Novartis’s heart failure treatment ‘Entresto (valsartan+ sacubitril) again ended with the victory of the Korean generic companies. If the companies succeed in winning the remaining 2 suits, the companies will be one step closer to the early release of their generics. Generic companies win first and second tr
